Expression and Purification of a Natural N-Terminal Pre-ligand Assembly Domain of Tumor Necrosis Factor Receptor 1 (TNFR1 PLAD) and Preliminary Activity Determination

被引:22
作者
Cao, Jin [1 ]
Meng, Fang [1 ]
Gao, Xiangdong [1 ]
Dong, Hongxia [1 ]
Yao, Wenbing [1 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
关键词
Tumor necrosis factor receptor (TNFR); Pre-ligand binding assembly domain (PLAD); GST fusion protein; L929; cells;
D O I
10.1007/s10930-011-9330-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
A domain at the NH2 terminal (N-terminal) of tumor necrosis factor receptor (TNFR) termed the pre-ligand binding assembly domain (PLAD). The finding that PLAD can mediate a selective TNFR assembly in previously researches provides a novel target to the prevention of TNFR signaling in immune-mediated inflammatory diseases (IMID). In this study, a natural N-terminal TNFR1 PLAD was obtained for the first time through the methods of GST-tag fusion protein expression and enterokinase cleavage. After purification with a Q Sepharose Fast Flow column, a natural N-terminal TNFR1 PLAD which purity was up to 95%, was obtained and was identified using Nano LC-ECI-MS/MS. Secondary structure analysis of PLAD was carried out using circular dichroism spectra (CD). After that, the TNFR1 PLAD in vitro anti-TNF alpha activity and the specific TNFR1 affinity were determined. The results proved that the natural N-terminal TNFR1 PLAD can selectively inhibit TNF alpha bioactivity mainly through TNFR1. It infers an effective and safe strategy for treating variety of IMID with a low risk of side effects in future.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 28 条
[1]
Infliximab neutralizes the suppressive effect of TNF-α on expression of extracellular-superoxide dismutase in vitro [J].
Adachi, Tetsuo ;
Toishi, Taisuke ;
Takashima, Eiji ;
Hara, Hirokazu .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (10) :2095-2098
[2]
STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS [J].
ADERKA, D ;
ENGELMANN, H ;
MAOR, Y ;
BRAKEBUSCH, C ;
WALLACH, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :323-329
[3]
CHARACTERIZATION OF RECEPTORS FOR HUMAN-TUMOR NECROSIS FACTOR AND THEIR REGULATION BY GAMMA-INTERFERON [J].
AGGARWAL, BB ;
EESSALU, TE ;
HASS, PE .
NATURE, 1985, 318 (6047) :665-667
[4]
TNF-mediated inflammatory disease [J].
Bradley, J. R. .
JOURNAL OF PATHOLOGY, 2008, 214 (02) :149-160
[5]
Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].
Brown, SL ;
Greene, MH ;
Gershon, SK ;
Edwards, ET ;
Braun, MM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158
[6]
Targeting TNF-α receptors for neurotherapeutics [J].
Chadwick, Wayne ;
Magnus, Tim ;
Martin, Bronwen ;
Keselman, Aleksander ;
Mattson, Mark P. ;
Maudsley, Stuart .
TRENDS IN NEUROSCIENCES, 2008, 31 (10) :504-511
[7]
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function [J].
Chan, FKM .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :50-53
[8]
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling [J].
Chan, FKM ;
Chun, HJ ;
Zheng, LX ;
Siegel, RM ;
Bui, KL ;
Lenardo, MJ .
SCIENCE, 2000, 288 (5475) :2351-2354
[9]
CHAN KF, 2000, IMMUNITY, V4, P419
[10]
TNF-R1 signaling: A beautiful pathway [J].
Chen, GQ ;
Goeddel, DV .
SCIENCE, 2002, 296 (5573) :1634-1635